" class="no-js "lang="en-US"> XNK Therapeutics Archives - Medtech Alert
Friday, March 01, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

XNK Therapeutics Appoints Hugo Petit as Chief Financial Officer

XNK Therapeutics today announced the appointment of Hugo Petit as Chief Financial Officer (CFO) and […]

XNK Receives EU Tissue Establishment Certificate

XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This […]

XNK Therapeutics Raises SEK 132 Million to Accelerate Growth

XNK Therapeutics AB (“XNK”) today announced it has secured a private placement of SEK 132 million, […]

XNK Therapeutics Appoints Markus Thor as Chief Business Officer

XNK Therapeutics AB today announced the appointment of Markus Thor as Chief Business Officer, effective September 6th. He […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more